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Abstract
Background Early clinical trials, mostly in the setting of
melanoma, have shown that dendritic cells (DCs) expressing
tumor antigens induce some immune responses and some
clinical responses. A major difficulty is the extension to other
tumors, such as breast carcinoma, for which few defined tumor-
associated antigens are available. We have demonstrated,
using both prostate carcinoma and melanoma as model
systems, that DCs loaded with killed allogeneic tumor cell lines
can induce CD8+  T cells to differentiate into cytotoxic T
lymphocytes (CTLs) specific for shared tumor antigens.
Methods The present study was designed to determine
whether DCs would capture killed breast cancer cells and
present their antigens to autologous CD4+ and CD8+ T cells.
Results We show that killed breast cancer cells are captured by
immature DCs that, after induced maturation, can efficiently
present MHC class I and class II peptides to CD8+ and CD4+ T
lymphocytes. The elicited CTLs are able to kill the target cells
without a need for pretreatment with interferon gamma. CTLs
can be obtained by culturing the DCs loaded with killed breast
cancer cells with unseparated peripheral blood lymphocytes,
indicating that the DCs can overcome any potential inhibitory
effects of breast cancer cells.
Conclusion Loading DCs with killed breast cancer cells may be
considered a novel approach to breast cancer immunotherapy
and to identification of shared breast cancer antigens.
Keywords: breast cancer, cell death, dendritic cells, immunotherapy, tumor immunity
Introduction
The concept of cancer immunotherapy has been energized
in the past decade by the molecular identification of human
cancer antigens [1-6]. These therapeutic approaches were
further facilitated through identification of in vitro culture
methods, allowing generation of large numbers of dendritic
cells (DCs) [7-9] on which the cancer antigens can be pre-
sented to T cells [10-15]. Numerous studies in animals
have demonstrated that immunization with tumor antigen-
loaded DCs induces protective antitumor responses [16-
19]. However, optimal antigen loading strategies for human
trials still remain to be determined.
The most commonly used, clinical grade approach is based
on loading empty MHC class I molecules with exogenous
peptides. This approach is limited, however, by peptide
restriction to a given human leukocyte antigen (HLA) type,
by induction of cytotoxic T lymphocyte (CTL) responses
only, and by limitation of the induced responses to defined
tumor-associated antigens.
We have demonstrated that DCs loaded with killed alloge-
neic tumor cell lines can induce CD8+ T cells to differenti-
ate into shared tumor antigen-specific effectors, using both
prostate carcinoma and melanoma as model systems
[20,21]. Such an approach offers new possibilities for
tumor-associated antigen delivery to DCs because the use
of tumor cells as a source of antigens should provide both
MHC class I and class II epitopes, leading to a diverse
immune response involving many clones of CTLs and
ATCC = American Type Culture Collection; cpm = counts per minute; CTL = cytotoxic T lymphocyte; DC = dendritic cell; ELISA = enzyme-linked 
immunosorbent assay; FCS = fetal calf serum; FITC = fluorescein isothiocyanate; HLA = human leukocyte antigen; IL = interleukin; IFN-γ = interferon 
gamma; mAb = monoclonal antibody; MHC = major histocompatibility complex; PBL = peripheral blood lymphocytes; PBS = phosphate-buffered 
saline; TNF-α = tumor necrosis factor alpha.Breast Cancer Research    Vol 6 No 4    Neidhardt-Berard et al.
R323
CD4+ T cells. The use of tumor cells in such an approach
should also provide a broad spectrum of presented tumor-
associated antigens, resulting in a broader repertoire of
elicited T-cell responses.
We aimed to apply this knowledge to breast carcinoma, a
tumor known to be relatively nonimmunogenic. This
reputed nonimmunogenicity may originate from the inhibi-
tory effects of breast cancer on DC growth and DC differ-
entiation, which depend on the secretion of cytokines such
as IL-6, monocyte colony-stimulating factor and vascular
endothelial growth factor [22-25]. Therefore, even though
our earlier work in melanoma and prostate carcinoma dem-
onstrated the validity of loading DCs with killed tumor cells
to elicit specific T-cell immunity, this approach needed to
be tested in a setting of breast cancer. Indeed, each type
of tumor represents its own entity; for example, different tis-
sue origins render extrapolations from one tumor to another
difficult, necessitating separate analysis.
Herein we show that DCs can capture killed breast cancer
cells and can subsequently activate CD4+ T cells as well as
CD8+ T cells. This represents a novel approach for devel-
opment of DC-based vaccination protocols in breast can-




The complete culture medium was RPMI 1640, 1% L-
glutamine, 1% penicillin/streptomycin, 50 µM 2-mercap-
toethanol, 1% sodium pyruvate, 1% essential amino acids,
and heat-inactivated 10% FCS (Life Technologies, Grand
Island, NY, USA). For T-cell cultures, FCS was replaced by
10% human serum AB (Gemini Bio-products, Woodland,
CA, USA). Granulocyte–monocyte colony-stimulating fac-
tor (Leukine, Immunex, Seattle, WA, USA), soluble CD40
ligand (Immunex), and IL-7 (Immunex or R&D System, Min-
neapolis, MN, USA) were used at the respective concentra-
tions of 100 ng/ml, 200 ng/ml and 10 IU/ml. IL-4 (Schering-
Plough, Kenilworth, NJ, USA, [kindly provided by S. Narula]
or R&D System) was used at 5 ng/ml, and IL-2 (Genzyme
Co., Cambridge, MA, USA) was used at 10 IU/ml.
Cycloheximide and the DNA dye 7-aminoactinomycin D
were obtained from Sigma (St Louis, MO, USA). Anti-Fas
mAb, clone CH11 (Beckman-Coulter, Miami, FL, USA),
was used at 1 µg/ml. Interferon gamma (IFN-γ) was used at
100 ng/ml (Actimune, InterMune Pharmaceuticals, MD,
USA).
Cell lines
The MCF-7 and HCC1806 breast cancer cell lines were
established by Dr A Gazdar and Dr J Minna at UTSW Med-
ical Center, Dallas and are available from the ATCC (Rock-
ville, MD, USA). The K562 and LnCAP prostate carcinoma
cell line were from the ATCC. All cell lines were maintained
in culture medium. HCC1806 cells were killed by treatment
with anti-Fas mAb (CH11, 1 µg/ml for 7 hours) followed by
cycloheximide sensitization (50 µg/ml). MCF-7 cells were
killed by gamma irradiation (150 Gy, and then cultured for
48 hours in serum-free medium) followed by tumor necrosis
factor alpha (TNF-α) sensitization (24 hours at 100 ng/ml).
Monocyte-derived DCs
Monocyte-derived DCs were generated from Ficoll-sepa-
rated peripheral blood mononuclear cells of HLA-A201+
healthy volunteers (IRB 097-053). Monocytes were
enriched by adherence and were cultured with granulo-
cyte–monocyte colony-stimulating factor and IL-4 (>90%
CD1a+ DCs at day 5). DC maturation was induced by 48
hour culture with soluble CD40 ligand, with monocyte-con-
ditioned media or with the combination of IL-1, IL-6 and
TNF-α.
T-cell purification
Purified CD4+ and CD8+ T cells (autologous to the DCs)
were obtained by peripheral blood mononuclear cell deple-
tion with CD4 mAb (13B8.2), CD8 mAb (B9.11), CD14
mAb (RM 052), CD16 mAb (3G8), CD19 mAb (J4,119),
CD56 mAb (NKH-1), anti-HLA-DR mAb (B8.12.2) and
antiglycophorin A mAb (D2.10) (all from Immunotech, Mar-
seille, France), and with goat anti-mouse IgG Dynabeads
(Dynal, Lake Success, NY, USA).
Confocal analysis
Cells were allowed to adhere on polylysine-coated slides
(Baxter, Deerfield, IL, USA) for 30 min at room temperature
and the supernatant was then removed. After fixation with
4% paraformaldehyde in PBS, cells were washed with
PBS and mounted. Confocal microscopy was performed
using a Leica TCS-NT SP (Leica, Deerfield, IL, USA)
equipped with argon, krypton, and helium/neon lasers, and
using a spectrophotometer to separate the detection chan-
nel of FITC (510–550 nm) and 7-aminoactinomycin D
(600–660 nm).
T-cell proliferation
T-cell proliferation was measured by thymidine incorpora-
tion after 5 days of culture of tumor-loaded DCs and autol-
ogous T cells.
Cytokine production
The cytokine production in day 6 supernatants was deter-
mined by ELISA using kits from Pharmingen (San Diego,
CA, USA; IL-4, IL-10 and IFN-γ) according to the manufac-
turer's suggestions.
Generation of CTLs
Tumor-loaded DCs were cultured with autologous purified
CD8+ T cells or autologous peripheral blood lymphocytesAvailable online http://breast-cancer-research.com/content/6/4/R322
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(PBL) at 105 DCs and 106 T cells. Cocultures were restim-
ulated weekly (a total of three stimulations) and supple-
mented with IL-7 (10 IU/ml in weeks 1 and 2), and IL-2 (10
IU/ml in weeks 2 and 3). The CTL activity was measured in
a standard 4-hour 51Cr-release assay, where the 51Cr-
labeled (NEN Life Science Products Perkin Elmer, Boston,
MA, USA) targets were exposed to cultured T cells and
lysis was measured after 4 hours of coculture. The percent-
age of killed cells was calculated using the formula: per-
centage of release = 100 × (counts per minute [cpm]
experiment - cpm spontaneous release)/(cpm maximum
release - cpm spontaneous release).
Results
DCs capture killed breast cancer cells
MCF-7 and HCC1806 are HLA-A201+ breast cancer cell
lines. MCF-7 cells have characteristics of differentiated
mammary epithelial cells, express estrogen receptor and
are susceptible to TNF. HCC1806 cells are less differenti-
ated and do not express estrogen receptor. HCC1806
cells are sensitive to Fas-induced apoptosis following
cycloheximide sensitization (Fig. 1a). MCF-7 cells are Fas
resistant but could be killed by a combination of gamma
irradiation (150 grays) and serum starvation. Because both
HCC1806 and MCF-7 grow as adherent cells and detach
Figure 1
Immature dendritic cells (DCs) capture killed breast cancer cells Immature dendritic cells (DCs) capture killed breast cancer cells. (a) HCC1806 cells are treated with treated with cycloheximide (50 mg/ml) in a 
sensitization step. After 2 hours at 37°C, anti-Fas antibody (CH11; Immunotech) is added at a concentration of 1 mg/ml and the cells are incubated 
for the indicated period of time. (b) 7-Aminoactinomycin D (7AAD)-labeled killed breast cancer cells are incubated for 1 hour at 37°C with CD1a-
labeled immature monocyte derived DC at a 1:1 ratio. The capture is determined by flow cytometry (the double-positive CD1a/7AAD represents the 
DCs that have captured killed breast cancer cells) and confirmed by confocal microscopy (c). Propidium iodide.Breast Cancer Research    Vol 6 No 4    Neidhardt-Berard et al.
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when dying, the nonadherent fraction can be used as a
convenient source of killed cells for DC loading.
Immature monocyte-derived DCs were able to capture
killed breast cancer cells after 1 hour of incubation at a ratio
of 1:1 at 37°C (Fig. 1b,1c). Flow cytometry analysis and
confocal microscopy, using 7-aminoactinomycin D-labeled
killed breast cancer cells and CD1a-labeled immature DCs,
show significant phagocytosis. Loaded DCs that were
recultured for 48 hours with cytokines survived as well as
unloaded cells, and were as efficient in inducing the prolif-
eration of allogeneic naïve T cells (data not shown). This
demonstrates that the capture of killed breast cancer cells
does not grossly affect DC function.
DCs loaded with killed breast cancer cells induce 
proliferation of autologous IFN-γ, producing CD4+ T cells
We next determined whether DCs that captured killed allo-
geneic breast tumor cells can present cell-derived antigens
to induce CD4+ T-cell proliferation. Immature DCs were
thus loaded with killed breast cancer cells, were induced to
mature in 48 hour culture with either CD40 ligand or
cytokine cocktail, and were used as stimulators in coculture
with autologous CD4 T cells.
CD4 T-cell proliferation was found only in cocultures with
tumor-loaded DCs (Fig. 2a) but not in cultures with either
unloaded DCs or killed breast cancer cells only (data not
shown). The proliferating autologous CD4+  T cells
secreted high levels of IFN-γ (Fig 2b) and neither IL-4 nor
IL-10 could be detected (data not shown).
DCs loaded with killed breast cancer cells induce 
differentiation of CD8 T cells into CTLs
We next determined whether DCs loaded with killed breast
cancer cells elicit CTLs able to kill the tumor cells used for
immunization. Tumor-loaded and matured HLA-A201+ DCs
were used to stimulate, at weekly intervals, purified autolo-
gous CD8+ T cells over a 3-week culture period.
As shown in Fig. 3a, loaded DCs induced differentiation of
CTLs able to kill HCC1806 cells at 37 ± 2% specific lysis.
The treatment of targets with IFN-γ increases their sensitiv-
ity to CTLs with 60 ± 9% specific lysis (mean ± standard
error, n = 3). The observed lysis is not due to natural killer
cells because K562 cells are not lysed. As expected, T
cells cultured with unloaded DCs are unable to kill
HCC1806 cells. HLA-A201+  CTLs generated with
HCC1806-loaded DCs were unable to kill the HLA-A201+
Figure 2
Dendritic cells (DCs) loaded with killed breast cancer (BrCa) cells induce CD4+ T-cell proliferation with a strong T helper type 1 cell polarization Dendritic cells (DCs) loaded with killed breast cancer (BrCa) cells induce CD4+ T-cell proliferation with a strong T helper type 1 cell polarization. 
Unloaded DCs and HCC1806-loaded DCs are cultured with purified CD4+ T cells. (a) T-cell proliferation is determined by thymidine incorporation 
at day 5. No proliferation is detected when CD4+ T cells are cultured with killed BrCa only without DCs (data not shown). (b) Supernatants of DC T-
cell cultures are analyzed by ELISA for the levels of interferon gamma (IFN-γ). Results are representative of two experiments.Available online http://breast-cancer-research.com/content/6/4/R322
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prostate carcinoma cell line LnCap, suggesting a lack of
shared tumor antigens between these two cell lines. How-
ever, HCC1806-primed HLA-A201+ CTLs were also una-
ble to kill the HLA-A201+ MCF-7 breast cancer cells.
Because breast cancer cells have been shown to inhibit
DC functions as well as CD4 T-cell differentiation, we ana-
lyzed CTL differentiation from unseparated PBL. The PBL
were cultured with mature DCs loaded with killed breast
cancer cells for 3 weeks (three stimulations) without add-
ing supplementary cytokines (IL-7 or IL-2). As shown in Fig.
3, cultured PBL composed of 80% CD4+ T cells are able
to kill the breast cancer cells used for the immunization,
either MCF-7 cells (Fig. 3c) or HCC1806 cells (Fig. 3d). As
already described, IFN-γ-treated targets were found to be
more sensitive to CTLs. DCs loaded with killed breast can-
cer cells can thus induce CTLs able to kill the tumor used
for immunization.
Discussion
Given the limited availability of defined breast tumor-asso-
ciated antigens, the present study was designed to identify
conditions permitting the loading of DCs with killed allo-
genic breast cancer cell lines. This involved a two-pronged
strategy that would allow the development of new breast
cancer vaccines at two levels. First was the preparation of
vaccines that may be used in patients suffering from breast
cancer, which would capitalize on the response to
'unknown' shared breast cancer antigens. Then there was
the identification of such unknown antigens through clon-
ing of elicited T cells.
Figure 3
Dendritic cells (DCs) loaded with killed breast cancer cells induce autologous CD8 T-cell differentiation into cytotoxic lymphocytes (CTLs) Dendritic cells (DCs) loaded with killed breast cancer cells induce autologous CD8 T-cell differentiation into cytotoxic lymphocytes (CTLs). Purified 
CD8+ T cells are cultured for 3 weeks with unloaded DCs (UL-DC) or with DCs loaded with killed HCC1806 (L-DC). T cells are tested in a 4-hour 
chromium release assay, using HCC1806 cells as targets and K562 cells as controls for natural killer activity (mean ± standard error, n = 3) (a), as 
well as unrelated HLA-A201+ tumor cell lines, prostate cancer cells (Ln-CAP) and another breast cancer cell (MCF-7) (b). No CTLs are elicited 
when T cells are cultured with killed breast cancer cells without the DCs (data not shown). In another set of experiments, peripheral blood lym-
phocytes (CD4+ and CD8+ T cells) are cultured for 3 weeks with UL-DC, or with DCs loaded with killed MCF-7 (c) or with L-DC (d). Results are rep-
resentative of two experiments.Breast Cancer Research    Vol 6 No 4    Neidhardt-Berard et al.
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In the present study, we identified clinical-grade conditions
that yield killed breast cancer cells, which can be captured
by DCs. The captured breast cancer cells were processed
by DCs to generate both class I and class II peptides com-
plexes recognized by CD8+ T cells and CD4+ T cells,
respectively. To our knowledge, this is the first study that
demonstrates the generation of breast cancer-specific
CTLs, using DCs loaded with killed allogeneic breast can-
cer cell lines. The major question that arises is the nature of
antigens presented by loaded DCs against which the T
cells have been primed (i.e. are they breast cancer-specific
antigens or alloantigen-specific antigens?).
Our previous studies with both prostate carcinoma and
melanoma indicated that a possible generation of allo-spe-
cific T cells did not prevent the development of CTLs spe-
cific for shared tumor antigens, as identified by the ability of
primed CTLs to kill peptide-pulsed T2 cells. Indeed, PSA-
specific CTLs were generated when using DCs loaded
with prostate carcinoma cells [21], while MART/Tyrosi-
nase/GP-100/MAGE-3-specific CTLs could be elicited
culturing CD8+  T cells with DCs loaded with killed
melanoma cells [20].
At variance with these earlier findings in melanoma and
prostate carcinoma, here we were unable to establish spe-
cificity of elicited CTLs against known tumor antigens such
as TERT, focal adhesion kinase-derived peptides or c-erb-
2. This would suggest that in the case of breast cancer the
alloantigen presentation by loaded DCs overshadows the
presentation of tumor antigens, and would explain the lack
of cross-killing between the two breast cancer cell lines
used for experiments. An alternative explanation is that
these antigens are not immunodominant antigens pre-
sented by loaded DCs. Indeed, owing to their unique bio-
logical characteristics, the two breast cancer cell lines that
we have used might provide very different immunodominant
tumor-associated antigen epitopes. MCF-7 cells are highly
differentiated mammary epithelial cells and express estro-
gen receptor, while HCC1806 cells are less differentiated
and do not express estrogen receptor.
Further studies are thus needed to determine the potential
therapeutic value of DCs loaded with killed allogeneic
breast cancer cells. The demonstration here that DCs
loaded with killed allogeneic breast cancer cells can induce
CTL differentiation provides a novel approach for identifica-
tion of shared breast cancer antigens through T-cell
cloning.
Conclusion
Loading DCs with killed breast cancer cells may be consid-
ered a novel approach to breast cancer immunotherapy
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